Silencing histone deacetylase 6 ameliorates retinal ischemia-reperfusion injury by inhibiting ferroptosis via regulating the HMGB1/NRF2 pathway

Authors: Wu, Xiaoli; Sun, Qun; Yang, Xueli

Source journal: Tissue & cell (2026-11-13)

DOI: 10.1016/j.tice.2026.104137

Abstract

This study aimed to clarify the role of histone deacetylase 6 (HDAC6) in regulating ferroptosis via the high-mobility group box 1 (HMGB1)/nuclear factor erythroid 2-related factor 2 (NRF2) pathway in retinal ischemia-reperfusion injury (RIRI). In vitro, an ischemia/reperfusion (I/R) model was established in HDAC6 knockdown Muller cells, and treated with the ferroptosis inducer Erastin. Cell viability, reactive oxygen species (ROS) and mitochondrial membrane potential were analysed using CCK8, flow cytometry, ELISA and Western blot, related biochemical indexes, and protein expressions (HDAC6, FTH1, TFR-1, GPX4). To study the role of the HMGB1/NRF2 pathway, a co-transfected cell line with HDAC6 knockdown and HMGB1 overexpression was constructed and subject to the above assays. Furthermore, a rat RIRI model was established for in vivo validation. The results showed that I/R significantly reduced cell viability, increased the levels of ROS, JC-1 monomer, MDA, LPO and Fe(2)(+), decreased GSH, and promoted ferroptosis. HDAC6 knockdown ameliorated I/R injury, which was reversed by Erastin or HMGB1 overexpression. In RIRI rats, HDAC6 knockdown improved retinal pathology, inhibited apoptosis and ferroptosis, while recombinant human HMGB1 abrogated these effects. Collectively, silencing HDAC6 can inhibit ferroptosis via modulation of the HMGB1/NRF2 pathway, thereby ameliorating RIRI.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.